La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Apogee Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Apogee Therapeutics..

Apogee Therapeutics (NASDAQ:APGE) Azioni, Catena delle Opzioni

APOGEE THERAPEUTICS INC

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Apogee Therapeutics Inc

Earnings

Press Releases

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

News

Health Care

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

IPOs

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Financing

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

APGE

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

ADMA Biologics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

Cidara Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

GRAIL

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Comments

Apogee Therapeutics

Apogee Therapeutics (APGE) Opzioni

Apogee Therapeutics (NASDAQ:APGE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO